or Try an Advanced Search...

    ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    TWST D -3.94 8.85
    RXRX F -6.37 6.86
    CDNA C -0.96 6.66
    CRSP F -2.98 6.16
    NTLA F -6.57 4.76
    VCYT C -2.67 4.34
    IONS F -2.47 4.26
    ADPT B -1.95 4.25
    TXG F -5.62 4.22
    NRIX D -1.69 3.85
    BEAM F -4.45 3.67
    NTRA B 0.19 3.48
    ARCT D 8.79 3.42
    SDGR F -4.04 3.31
    PSNL D -8.36 2.74
    GH F -3.57 2.57
    VEEV C -1.07 2.12
    ABSI F -5.24 1.95
    MRNA F -4.34 1.85
    AMGN D -0.59 1.83
    VRTX D 1.01 1.77
    PACB F -4.71 1.64
    ACCD F -2.60 1.55
    REGN D -0.41 1.18
    EXAS C -0.12 1.15
    CMPS F -5.40 1.04
    INCY B 2.97 1.03
    CERS F -2.30 1.02
    BFLY C -6.21 1.00
    MASS F -2.02 0.88
    QSI F -4.78 0.80
    PRME F -10.85 0.75
    RPTX D 0.87 0.66

    Represented by ETF Holdings

    Keywords: Biotechnology Cancer Biopharmaceutical Drug Discovery Biology Life Sciences Medicine Genomics Nasdaq 100 S&P 500 Genetics Molecular Biology Precision Medicine Telehealth Telemedicine Acid Blood Test Breakthrough Therapy CRISPR Disease
    Industries: Biotechnology Diagnostics & Research Health Information Services Health Information Services Medical Devices Drug Manufacturers - Major Medical Care Facilities

    Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

    Date Stock Title
    Oct 1 ARCT Unveiling 3 Analyst Insights On Arcturus Therapeutics
    Oct 1 VEEV 17 Analysts Assess Veeva Systems: What You Need To Know
    Oct 1 TXG 10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting
    Oct 1 PRME PRME Stock Rises 11.8% on Collaboration With Bristol Myers
    Oct 1 MRNA The Covid Era Tech Promises To Reinvent Cancer Treatment
    Oct 1 AMGN Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi
    Oct 1 ARCT ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
    Oct 1 MRNA ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
    Oct 1 MRNA Is Moderna, Inc. (MRNA) the Worst Performing Stock to Buy on the Dip?
    Oct 1 MRNA MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
    Oct 1 PRME BMS and Prime ink potential $3.5bn deal to develop T cell therapies
    Oct 1 IONS Ionis gets U.S. FDA fast track designation for its Alexander disease treatment
    Oct 1 MRNA Company News for Oct 1, 2024
    Oct 1 PACB PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore
    Oct 1 AMGN LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
    Oct 1 MRNA IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
    Oct 1 NTLA Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
    Oct 1 IONS Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
    Oct 1 VRTX 5 FDA decisions to watch in the fourth quarter
    Oct 1 MRNA Moderna doses first subject in Phase III trial of mRNA norovirus vaccine in US
    Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
    Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics
    Back to the Main ARKG Page...